Compare · PRPO vs RVTY
PRPO vs RVTY
Side-by-side comparison of Precipio Inc. (PRPO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRPO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 427.8x PRPO ($40.4M).
- Over the past year, PRPO is up 19.3% and RVTY is up 60.0% - RVTY leads by 40.7 points.
- RVTY has hit the wire 5 times in the past 4 weeks while PRPO has been quiet.
- RVTY has more recent analyst coverage (23 ratings vs 0 for PRPO).
- Company
- Precipio Inc.
- Revvity Inc.
- Price
- $21.64-2.52%
- $152.62-1.34%
- Market cap
- $40.4M
- $17.26B
- 1M return
- -18.28%
- +4.01%
- 1Y return
- +19.29%
- +60.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 23
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest PRPO
- Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Financial Results
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Shareholder Update Call
- Director Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)
- Director Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)
- Director Cohen David Seth was granted 520 shares, increasing direct ownership by 0.95% to 55,199 units (SEC Form 4)
- Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio to Present at the Planet MicroCap Las Vegas
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery